

Competition and Patent Law in the Pharmaceutical Sector

An International Perspective

Edited by

Giovanni Pitruzzella
Gabriella Muscolo



Wolters Kluwer

Published by:

Kluwer Law International B.V.
PO Box 316
2400 AH Alphen aan den Rijn
The Netherlands
Website: www.wklawbusiness.com

Sold and distributed in North, Central and South America by:

Wolters Kluwer Legal & Regulatory U.S.
7201 McKinney Circle
Frederick, MD 21704
United States of America
Email: customer.service@wolterskluwer.com

Sold and distributed in all other countries by:

Turpin Distribution Services Ltd
Stratton Business Park
Pegasus Drive, Biggleswade
Bedfordshire SG18 8TQ
United Kingdom
Email: kluwerlaw@turpin-distribution.com

Printed on acid-free paper.

ISBN 978-90-411-5927-4

© 2016 Kluwer Law International BV, The Netherlands

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher.

Permission to use this content must be obtained from the copyright owner. Please apply to: Permissions Department, Wolters Kluwer Legal & Regulatory U.S., 76 Ninth Avenue, 7th Floor, New York, NY 10011-5201, USA. Website: www.wklawbusiness.com

Printed in the United Kingdom.

Editors

Gabriella Muscolo Commissioner at the Italian Competition Authority, former Judge at the specialized section for IP and Competition Law Litigation of the Court of Rome, former member of the Enlarged Board of Appeal of the European Patent Office, author of several publications in the field of IP Law, Competition Law and Company Law and usual lecturer in several Universities in Italy and abroad.

Giovanni Pitruzzella Chairman of the Italian Competition Authority – full professor of Constitutional Law University of Palermo – former lawyer at the bar of Palermo, author of several publications in the field of European Constitutional Law and Competition Law.

Contributors

Filippo Arena serves, since November 2013, as Chief of Cabinet at the Italian Competition Authority, where he previously was the Legal Advisor. After a graduation in Law at the University of Messina in 1991, he became State Lawyer in 1997, representing Italy before the European Court of Justice and also being in charge of litigations of the Italian Competition Authority, the Italian Parliament and those between Government and Regions. He is a lecturer and speaker at conferences related to competition policy.

Sir Gerald Barling is a Justice of the Chancery Division of the High Court of England and Wales and was President of the Competition Appeal Tribunal from 2007–2013. He has been an Acting Deemster in the Isle of Man Court of Appeal. Educated at St Mary's College, Blackburn and New College, Oxford (where he was later a lecturer in law for several years). He was called to the Bar by the Middle Temple in 1972, where he was elected a Bencher in 2001, and was appointed Queen's Counsel in 1991. He was a Deputy High Court Judge and also sat as a Recorder on the Midland Circuit. After practising at the Bar in Manchester for several years, from 1981 onwards his practice was based at Brick Court Chambers in London, where he specialized in public law and European Union law and was frequently instructed by both UK government and private clients, and appeared both in British and European Courts of Justice. His work encompassed virtually every field of European law.

Ginevra Bruzzone is Deputy Director General of Assonime, in Rome, where she is in charge of EU and Italian competition law, consumer protection, IP law and regulation. She was formerly Senior Economist at the Research Department of the Italian Competition Authority, from 1991 to 2000. She teaches a course on Competition and Consumer Protection in the EU at the Luiss School of European Political Economy (SEP), in Rome. She is a member of the Advisory Board of the Italian Transport Regulation Authority.

Sara Capozzi is a lawyer at Assonime, in the Enterprise, Competition and Regulation Unit. Her research areas include competition law, IP law and regulation. She earned a

MA in Antitrust and Regulation from the University of Rome ‘Tor Vergata’ and a MA in International Business Law from the University of Rome ‘La Sapienza’.

Beniamino Caravita is Full professor of Public Law in La Sapienza Rome University, Chairman of CdTA Lawyer Firm, author of several publications in the fields of Public Law, Competition Law, Company Law, Member of several Government Commissions and Editor of the Review ‘federalismi.it’.

Michael A. Carrier is Distinguished Professor at Rutgers Law School. He is the co-author of the leading IP/antitrust treatise, *IP and Antitrust Law: An Analysis of Antitrust Principles Applied to Intellectual Property Law*, the author of *Innovation for the Twenty-First Century: Harnessing the Power of Intellectual Property and Antitrust Law*, and the editor of *Critical Concepts in Intellectual Property Law: Competition*. He has written more than seventy-five book chapters and articles and is regularly quoted in leading media outlets. He has testified before the US Senate and other bodies, is a member of the Board of Advisors of the American Antitrust Institute, and is a past chair of the Antitrust and Economic Regulation section of the AALS.

Giovanni Cavani is a lawyer, born in Modena, 5 December 1950; admitted to the bar in 1976, Italy. Education: University of Modena (J.D., magna cum laude, 1973). Professor, Intellectual Property Law, Modena University. Author of several contributions on industrial and antitrust law, Intellectual Property and international contracts of technology transfer.

Roberto Chieppa has been appointed Secretary General of the Autorità Garante della Concorrenza e del Mercato since December 2011. Judge at the High Administrative Court (Consiglio di Stato) since February 2000. Previously he has been judge at the First Instance Administrative Court (1998–2000), judge at the Court of Auditors (1997–1998) and civil and criminal judge since 1991. Author of more than fifty publications in administrative law and competition law. Co-editor of specialized legal journals. Lecturer for university and post-graduate courses on administrative law and antitrust law.

Naval Satarawala Chopra is a Partner in the Competition Law Practice of Shardul Amarchand Mangaldas & Co., recently indicted by Global Competition Review in its list of top ‘Forty under Forty’ competition lawyers worldwide, acknowledged by Chambers & Partners, 2015 as a ‘master strategist’ who is known for his ‘ability to think out of the box and find solutions’, and by Chambers & Partners 2016 as ‘very knowledgeable, very well read and very smart’, author of several publications in the field of Competition Law. In 2014, Naval instituted a course on competition law at ILS Law College, Pune, where he teaches part time. He is qualified to practice in New York, England & Wales and India.

Avantika Chowdhury is a senior economist at Oxera Consulting LLP specialising in antitrust and intellectual property related issues. She has published extensively on these issues including co-authoring a book on the interactions of competition law with

other disciplines. She has a Ph.D. in economics and game theory from Pennsylvania State University, USA and regularly lectures in courses for competition authorities and judges.

Daryl Dingley is a partner at Webber Wentzel, and a former senior economist at the South African Competition Commission, specializes in competition law and has particular expertise in economics and international trade. He has authored a number of articles and is a co-author of a book on competition law, 'A Practical Guide to the South African Competition Act'.

Sir Christopher Floyd (The Rt Hon Lord Justice Floyd) has been a judge of the Court of Appeal for England and Wales since April 2013. From 2007 he was a judge of the Chancery Division of the High Court, a judge and subsequently judge in charge of the Patents Court, and a Deputy Chairman of the Competition Appeal Tribunal. Before becoming a judge, he practised as a barrister in intellectual property law from chambers at 11 South Square, Gray's Inn, becoming Queen's Counsel in 1992. Whilst in practice he was a Deputy Chairman of the Copyright Tribunal, Chairman of the Intellectual Property Bar Association and a Recorder.

Ian S. Forrester holds office of a Judge, General Court of the European Union. Retired Partner, White & Case; formerly Forrester Norall & Sutton. Hon Professor and Hon Doctor of Laws, Glasgow University; admitted to the bar in Scotland, New York, England and Belgium; Queen's Counsel (1988); Bencher, Middle Temple (2012). Author; advocate in several leading cases in national and European courts: *Magill*; *Bosman*; *Microsoft*; *IMS*; *Pfizer Animal Health*; *Government of Gibraltar v. Council*; *Glaxo Spain and Syfait et al. v. GlaxoSmithKline*; *Servier*; *Halcor*; *A v. National Blood Authority*; *Bellona Foundation v. EFTA*.

Mario Franzosi is a Visiting Professor of Intellectual Property at the University of Washington, Founding Partner of Avvocati Associati – Franzosi Dal Negro Setti, Chair of the Special Committee Designs AIPPI; Vice-President of the Italian Design Jury at the ADI (Italian Association of Designers), former President and founder; Member of the Bar of Milan since 1959. Author of key legal texts on Intellectual Property Law.

Alexander Gaigl is an economist at Oxera Consulting LLP. He specializes in competition economics and has worked on a wide range of competition cases in many industries across Europe, including in the pharmaceuticals sector. He has extensive experience in relation to the economic assessment of the interplay between competition and innovation. He advised clients in the context of several patent settlement investigations and has published articles on this topic.

Damien Geradin is the founding partner of EDGE Legal, a competition and IP boutique law firm based in Brussels. He is also a Professor of competition law & economics at Tilburg University, a Professor of Law at George Mason University School of Law, and a visiting Professor of Law at University College London. He is the author/co-author/

editor of 20 books and over 100 scientific papers. He is the co-editor of the Journal of Competition Law & Economics.

Gustavo Ghidini is a Professor of IP and Competition Law, University Luiss Guido Carli, Rome, and University of Milano. Director of the Observatory of IP, Competition and Communication Law/ DREAM, Luiss Guido Carli University.

Douglas H. Ginsburg is a Senior Judge, United States Court of Appeals, Washington DC; Professor of Law at George Mason University; Chairman of the Global Antitrust Institute International Board of Advisors; and a former Assistant Attorney General in charge of the Antitrust Division of the US Department of Justice.

Heinz Goddar is a European and German Patent and Trademark Attorney. He is a partner of Boehmert&Boehmert and works in its Munich office. He teaches as an Honorary Professor at Bremen University, Germany, and lectures at various other universities and institutions in Germany and abroad. He is a Past President of LES Germany and LES International. Furthermore, he has received a Gold Medal of LESI in 2004 and has been inducted into the IAM IP Hall of Fame in 2014.

Alan Gunderson is a Coordinator within the Competition Promotion Branch of the Competition Bureau Canada. He has led the Competition Bureau's recent initiative to update and expand its Intellectual Property Enforcement Guidelines. He has a Ph.D. in economics from Queen's University in Kingston, Ontario.

Willem A. Hoyng is a Professor of IP Law University Tilburg and managing partner of HOYNG ROKH MONEGIER.

Anne-Claire Hoyng has worked as a senior case handler for the Netherlands Competition Authority in the past. She obtained her Ph.D. in Economics in 2011. Since 2014 she works as Manager Competition Policy at Liberty Global. She also lectures the course Economics of Competition Law and Policy at the University of Utrecht.

Alexey Ivanov leads the Skolkovo-HSE Institute for Law and Development (Moscow, Russia), a joint venture of the National Research University – Higher School of Economics (HSE) and the Skolkovo Foundation, a Russian development institution. Alexey, since 2008, has taught at HSE a course on antitrust in the new economy as part of the educational program mandated by the Federal Antimonopoly Service of Russia and published prolifically on this and related topics.

Sir Robin Jacob is Professor of IP Law at University College London. He is a former member of the Court of Appeal of England and Wales and is currently an arbitrator and mediator as well as President of the Intellectual Property Judges' Association.

Ioannis Kokkoris holds a Chair in Law and Economics at the Centre for Commercial Law Studies, Queen Mary University of London, UK. He is also the Executive Director

of the Institute for Global Law Economics and Finance. He has authored and co-authored more than 15 books, more than 50 articles and 15 chapters in edited volumes. Professor Kokkoris has formerly served as Principal Case Officer/Economic Advisor in the Mergers branch at the Office of Fair Trading, UK where he dealt with leading cases such as NASDAQ/LSE, NYSE/Euronext, Global/GCap and was a member of the drafting team of the UK Merger Guidelines. He has also worked on abuse of dominance cases as well as cartels and other anticompetitive agreements cases.

Bruno Lasserre is the President – Autorité de la concurrence (France), Member of the Conseil d’État, the French supreme administrative court, which he joined in 1978 after graduating from École Nationale d’Administration (ENA), the French national school for civil service. After serving as Member of the board of the Conseil de la concurrence (1998–2004), he was appointed President in July 2004, and in this capacity pushed through a major reform that transformed it into the Autorité de la concurrence, responsible for merger review and competition advocacy in addition to antitrust enforcement. He has chaired the Autorité since then. He is also a Commander of the French Légion d’honneur and a Commander of the French Ordre national du Mérite.

Ana Paula Martinez is a partner with Levy & Salomão Advogados (Brazil). From 2007 to 2010, she was the head of the Antitrust Division of the Secretariat of Economic Law/Ministry of Justice, and co-headed the cartel sub-group of the International Competition Network. She is licensed to practice in Brazil and NY and served as an antitrust advisor to Unctad, to the World Bank and to the Government of Colombia. She holds an LL.M. from the University of São Paulo (USP) and from Harvard and a Ph.D. from USP. She is a Professor of Law at Fundação Getulio Vargas – Rio de Janeiro. She has received several prizes and awards for her antitrust work.

Pietro Merlino is a counsel at Cleary Gottlieb Steen & Hamilton LLP, based in Rome. He focuses on EU and Italian competition law. He appears frequently before the EU courts of law and Italian civil and administrative courts, as well as before the Directorate General for Competition of the European Commission and the Italian Competition Authority. He holds LL.M. degrees from the College of Europe and the University of Michigan Law School (Fulbright scholar) and a Ph.D. in EU competition law from the University of Naples “Federico II”. He regularly lectures at various academic institutions and international conferences and is the author of several publications on competition law issues.

Jan Bernd Nordemann is a certified German intellectual property, copyright and media lawyer. He is a partner of the German intellectual property boutique BOEHMERT & BOEHMERT, Berlin office. In 2007, he was appointed Honorary Professor at the Humboldt University of Berlin. Best Lawyers International 2015 and Legal 500 Germany 2015/2016 accords him special recognition for legal advice on copyright issues as well as in trademark and competition law. Nordemann is a co-author of ‘Fromm/

Nordemann’, one of the leading German copyright law commentaries, and he co-authored the commentary on European and German anti-trust law, ‘Loewenheim/Meessen/Riesenkampf’.

Cristoforo Osti is a Full Professor of Business Law at the School of Law of the University of Salento, Lecce. He is a partner at Chiomenti Studio Legale since 2012 where he leads the Competition Law Department. Before then he held the same position at Clifford Chance LLP. He is the author of monographs and articles on competition law and contract law and is a regular speaker at national and international conferences.

Hermes Pazzagli has extensive experience on PRC-related commercial law issues and is an arbitrator of the Shanghai International Arbitration Center and the Shenzhen Court of International Arbitration. He is fluent in Mandarin, Cantonese, Italian, French and Spanish. He currently heads the Shanghai practice of NCTM Shanghai. He has authored numerous articles on Chinese law in English and Italian on legal magazines and books.

Andrea Pezzoli holds the office of the Director General for Competition of the Italian Competition Authority, where he has worked since 1993 as head of the Investigative Directorate ‘Food, Pharmaceutical and Transport’ and as Chief Economist. He teaches Competition Issues at the University of Tor Vergata and at Luiss University in Rome. Author of several publications in the field of Competition Policy and Industrial Economics.

Piera Francesca Piserà is a Ph.D. Candidate in IP and Competition Law, University of Modena and Reggio Emilia. Since 2013, she has been collaborating with the Observatory of IP, Competition and Communication Law (OPICC/DREAM), Luiss Guido Carli University, Rome.

Luigi Prosperetti is a Professor of Economic Policy at the Faculty of Law, Università degli Studi di Milano. He studied economics at Bocconi, Milan (cum laude, 1976) and the London School of Economics (M.Sc., 1978; Ph.D., 1982). He has written extensively on regulatory and antitrust issues, and in 2009, he published *Il danno antitrust: una prospettiva economica*.

Enrico Adriano Raffaelli is a Lawyer specialized in national and European competition law, intellectual property law, commercial law, commercial litigation and national and international commercial arbitration; founding partner of the Rucellai & Raffaelli law firm; frequent lecturer on intellectual and industrial property rights, EU law and EU and national competition law at conferences and seminars; member of various antitrust associations.

Renella Reumerman (BA (Hons), BCL, LL.M.) is qualified as a solicitor in England and Wales in 2003. Following six years at law firm Freshfields Bruckhaus Deringer, she worked as a senior legal advisor and assistant director at the UK’s Office of Fair Trading

and the Competition Commission (as well as their successor, the Competition and Markets Authority). Currently she is a référendaire at the Competition Appeal Tribunal.

Graham Safty is a litigation associate at Williams and Connolly in Washington, DC, and a former law clerk to Judge Douglas H. Ginsburg. He graduated from The University of Chicago Law School, with Highest Honors, in 2013.

Alexandra Sidossis holds an LL.B. in European Legal Studies from the University of Kent at Canterbury, UK, and an LL.M. in Commercial Corporate Law from the Queen Mary University of London, UK.

Mario Siragusa is a partner at Cleary Gottlieb Steen & Hamilton LLP, based in the Rome and Brussels offices. He focuses on corporate and commercial matters and specializes in EU and Italian competition law as well as complex commercial litigation. He appears frequently before the European Court of Justice, the General Court of the European Union, the Directorate General for Competition of the European Commission, as well as the Italian Antitrust Authority and Italian civil and administrative courts. He lectures regularly at conferences throughout the United States and Europe and has published numerous articles in US and European legal journals. He is a professor at the College of Europe in Bruges and lectures at the Catholic University in Milan.

Toshiko Takenaka holds office of Washington Research Foundation/W Hunter Simpson Professor of Technology at University of Washington School of Law (Seattle, USA), and teaches US and comparative patent law and other technology related aspects of IP laws at universities in Asia and Japan. She will be a joint appointment between UW Law and Keio University School of Law (Tokyo, Japan) starting 2017 April.

Elisa Teti is a partner of the Rucellai & Raffaelli law firm; she focuses in EU and Italian competition law, intellectual property law and consumer protection law; she is author of several publications in the field of competition law.

Yaman Verma is a Senior Associate in the Competition Law Practice at Shardul Amarchand Mangaldas & Co, formerly an intern with the Competition Commission of India, author of several publications in the field of Competition Law. Yaman works with a wide range of international and domestic clients, most recently advising Microsoft (information technology); Vodafone (telecommunications); Apollo Tyres (automotives); and Coal India (natural resources).

Julian Waiblinger is a German attorney-at-law, and a partner of the German intellectual property boutique BOEHMERT & BOEHMERT, Berlin office. Besides counselling in copyright, trademark and competition law, IT licensing and contract law is a key area of his work. Another focus of his activity is antitrust law. He wrote his Ph.D. thesis about plagiarism in research and science. Besides his legal work his passion lies in music. He studied music at the Hanns Eisler Academy of Music Berlin and is an active percussionist; he has published several albums under a US records label.

Summary of Contents

Editors	v
Contributors	vii
Foreword	xxxiii
Preface	xxxv
PART I	
Pharmaceutical Patents and Competition Issues	1
CHAPTER 1	
The Perspective of Economics	3
The Economics of Competition Law and of Pharmaceutical Patents <i>Avantika Chowdhury & Alexander Gaigl</i>	5
The Procompetitive and Anticompetitive Impact of Patent Settlements <i>Ginevra Bruzzone & Sara Capozzi</i>	15
Originators versus Originators: Competition before the Market and Market Power beyond Dominance <i>Andrea Pezzoli</i>	31
Damages for Patent Infringements: The Interplay of Legal and Economic Perspectives in the Main European Jurisdictions <i>Luigi Prosperetti</i>	43
CHAPTER 2	
The Perspective of Law	51

Summary of Contents

Balancing the Human Right to Health with the Competition Law and the Intellectual Property Regime <i>Beniamino Caravita di Toritto</i>	53
The Dangers of Settling Patent Litigation <i>Ian S. Forrester</i>	67
Life-Cycle Management Strategies in the Pharmaceutical Patent Sector <i>Giovanni Pitruzzella</i>	77
Pharmaceutical Patents: Competition Law Goes Too Far <i>Robin Jacob</i>	85
What's in a Name: The Concept of Abuse in <i>Sui Generis</i> Abuses <i>Cristoforo Osti</i>	93
Abuse of Litigation, Abuse of Patent and Abuse of Dominance: Where Do We Stand? <i>Gabriella Muscolo</i>	107
Reverse Settlements in the European Union and the United States <i>Damien Geradin, Douglas H. Ginsburg & Graham Safty</i>	125
Co-marketing and Co-promotion Agreements <i>Enrico Adriano Raffaelli & Elisa Teti</i>	147
The New Unified European Patent Court and a New Patent Law: When a KU is Not a KU <i>Mario Franzosi</i>	167
PART II	
What Is Going on in National Systems?	183
CHAPTER 3	
The Perspective from Europe	185
FRANCE	
Raising Artificial Barriers against Generic Entry: The French Experience <i>Bruno Lasserre</i>	187
GERMANY	
Patent Settlements and Drug Discount Agreements in Light of European and German Antitrust Law <i>Heinz Goddar, Jan Bernd Nordemann & Julian Waiblinger</i>	205

GREECE	
The Status Quo and the Future of the Balance between Patent Law and Competition Law in the Pharmaceutical Sector in Greece <i>Ioannis Kokkoris & Alexandra Sidossis</i>	219
ITALY	
The Intersection between Competition Law and Intellectual Property Law: The Public Enforcement Approach Followed by The ICA <i>Filippo Arena & Roberto Chieppa</i>	239
ITALY	
Abuse of Patent Rights and Abuse of Dominant Position: The <i>Pfizer</i> Case <i>Gustavo Ghidini, Giovanni Cavani & Piera Francesca Piserà</i>	253
ITALY	
Antitrust Assessment of Co-marketing Agreements: A Diverging Approach between EU and Italy? <i>Mario Siragusa & Pietro Merlino</i>	273
NETHERLANDS	
Follow the Dutch? <i>Willem Hoyng & Anne-Claire Hoyng</i>	299
UNITED KINGDOM	
The Pharmaceutical Sector between Patent Law and Competition Law in the UK <i>Ioannis Kokkoris</i>	307
UNITED KINGDOM	
IP in the Pharmaceutical Sector in the UK: Some Recent Cases <i>Christopher Floyd</i>	345
UNITED KINGDOM	
Gaviscon: The Diagnosis and Treatment of Abuse of Dominance: Very Recent Changes in the Private Enforcement of Competition Rules in the UK <i>Gerald Barling & Renella Reumerman</i>	355
CHAPTER 4	
The International Approach	369
BRAZIL	
Competition Policy and Life Cycle Management: The Brazilian Experience <i>Ana Paula Martinez</i>	371

Summary of Contents

CANADA

- The Intersection of Canadian Competition and Intellectual Property Law:
Developments in the Pharmaceutical Sector
Alan Gunderson 381

CHINA

- The Development of China Antitrust Law and a Review of the Main Decision
on the Pharmaceutical Industry
Hermes Pazzaglino 395

INDIA

- The Interplay between Competition Law and Intellectual Property in the
Indian Pharmaceutical Sector: Deference Is Better than Cure
Naval Satarawala Chopra & Yaman Verma 419

JAPAN

- Japan's Pharmaceutical Industry and the Patent and Non-patent Incentives
for Pharmaceutical R&D
Toshiko Takenaka 431

RUSSIA

- The Interplay of Patents and Competition Law in the Russian Pharmaceutical
Sector: An Everlasting State of Transition
Alexey Ivanov 449

SOUTH AFRICA

- The Intersection between Patent Law and Competition law as It Relates to
the Pharmaceutical Sector in South Africa
Daryl Dingley 459

UNITED STATES

- Pharmaceutical Antitrust Law in the United States
Michael A. Carrier 477

- Index 489

Table of Contents

Editors	v
Contributors	vii
Foreword	xxxiii
Preface	xxxv
PART I	
Pharmaceutical Patents and Competition Issues	1
CHAPTER 1	
The Perspective of Economics	3
The Economics of Competition Law and of Pharmaceutical Patents <i>Avantika Chowdhury & Alexander Gaigl</i>	5
1 A Brief Introduction	5
1.1 Impact of Patents and Competition on Innovation: The Theory	7
1.2 Impact of Patents and Competition on Innovation: The Evidence	9
1.3 Patent Law and Competition Law: Is There a Conflict?	12
The Procompetitive and Anticompetitive Impact of Patent Settlements <i>Ginevra Bruzzone & Sara Capozzi</i>	15
1 Introduction	15
2 An Economic View of Reverse Payment Settlements	18
2.1 Interaction between Originator and Generic Companies within the Competitive Process	18
2.2 Restrictions of Entry and Value Transfer	20
2.3 Beyond Simple Stories: Adding Uncertainty to the Picture	20
2.4 Reverse Payment Settlements: The Full Story	22

Table of Contents

2.4.1	Reduction in the Branded Company Profits as a Consequence of Entry	23
2.4.2	Estimated Probability of Losing the Trial and Risk Aversion	23
2.4.3	Legal Expenses and Negative Hold-Up for the Patent Holder	24
2.4.4	Additional Features: Product Differentiation and Relaxing the Duopoly Assumption	24
2.4.5	Summing Up	25
3	The Application of Competition Rules to Reverse Payment Settlements	25
3.1	Relevance of the Institutional Setting	25
3.2	The Scenario Justifying a Negative Presumption against Reverse Payment Settlements	26
3.3	Outside the Hypothetical World	26
3.3.1	Non-interference with IP Matters as a Possible Approach	26
3.3.2	Case-by-Case Approaches	27
3.3.3	Inadequacy of a Restriction by Object Approach	28
3.3.4	Which Role for Competition Policy?	29
	Originators versus Originators: Competition before the Market and Market Power beyond Dominance	
	<i>Andrea Pezzoli</i>	31
1	Preliminary Remarks	31
2	Originators versus Originators: Competition beyond the Market	33
3	The Box of Tools and Competition for Future Markets	35
4	A Complementary Tool: Competition as a Process	39
5	Concluding Remarks	40
	Damages for Patent Infringements: The Interplay of Legal and Economic Perspectives in the Main European Jurisdictions	
	<i>Luigi Prosperetti</i>	43
1	Introduction	43
2	Lost Sales and Price Erosion	45
3	Irrecoverable Costs	46
4	Disruption of End-of-Patent-Life Care	46
5	Damage Recovery in Court: Unreasonable Royalties	47
6	Conclusions	49
	CHAPTER 2	
	The Perspective of Law	51
	Balancing the Human Right to Health with the Competition Law and the Intellectual Property Regime	
	<i>Beniamino Caravita di Toritto</i>	53
1	Intellectual Property and the Right to Health: An International View	53

2	Patents for Pharmaceutical Products: A Conflict between the Right to Health and the Intellectual Property Right	56
3	Rules and Flexibilities: An International Impact	58
4	A Comparative Analysis between the Human Right to Health, the Intellectual Property Right and the Protection of Competition	63
5	Conclusions	65
The Dangers of Settling Patent Litigation		
<i>Ian S. Forrester</i>		67
1	Introduction	67
2	Some Economic and Regulatory Context	68
3	Value Transfers	70
4	Anti-competitive Settlements	70
5	Pre-trial Nervousness and Uncertainty	71
6	The Public Interest?	72
7	The Overuse of the Notion of Restriction ‘By Object’	72
8	Where are the Limiting Principles?	73
9	What Precisely Is the Illegal Conduct?	74
10	A Patent Judge Comments	74
11	Conclusion	75
Life-Cycle Management Strategies in the Pharmaceutical Patent Sector		
<i>Giovanni Pitruzzella</i>		77
1	Introduction: Life-Cycle Management in IP-Intensive Industries	77
2	A Very Essential Case-Law Survey	80
	2.1 The AstraZeneca-Losec Case	81
	2.2 The Pfizer-Xalatan Case	82
3	Concluding Remarks	84
Pharmaceutical Patents: Competition Law Goes Too Far		
<i>Robin Jacob</i>		85
1	The Pharma Industry	85
2	Patents and Divisional Patents	87
3	Why the Decision in <i>Ratiofarm v. Pfizer</i> is Wrong, Antipatent and Unfair on Pfizer and Other European Countries	90
What’s in a Name: The Concept of Abuse in <i>Sui Generis</i> Abuses		
<i>Cristoforo Osti</i>		93
1	Introduction	93
2	The AstraZeneca Case	94
3	A Deluge of Cases	97
4	<i>Sui Generis</i> Abuse as Abuse of Rights	98

Table of Contents

5	<i>Sui Generis</i> Abuse as an Act of Unfair Competition	102
6	Conclusion: What the Overlap with Abuse of Rights and Unfair Competition Tells Us about <i>Sui Generis</i> Abuses	104
Abuse of Litigation, Abuse of Patent and Abuse of Dominance: Where Do We Stand?		
<i>Gabriella Muscolo</i>		
1	Introduction: Focus on Sham Litigation	107
2	The Right of Access to Courts and Its Abuse	108
3	The Abusive Litigation Doctrine and Tests	111
4	Focus on the Abuse of Injunction	112
5	Vexatious Litigation in the Pharmaceutical Sector between Patent Protection and Competition Issues	118
6	Conclusions: Some Critical Remarks	123
Reverse Settlements in the European Union and the United States		
<i>Damien Geradin, Douglas H. Ginsburg & Graham Safty</i>		
1	Introduction	125
2	United States	125
2.1	Statutory Framework	126
2.2	The Actavis Decision	128
2.3	Important Questions after Actavis	128
2.3.1	What Is a Reverse-Payment?	129
2.3.2	When Is a Reverse-Payment ‘Large and Unjustified?’	132
2.3.3	How Will Courts Evaluate the Procompetitive Effects of a Reverse-Payment Settlement Agreement?	134
2.3.4	What Is the Role of the FTC in Regulating Reverse-Payment Settlement Agreements?	136
3	European Union	137
3.1	Regulatory Context	137
3.2	Evolution of the Assessment of Patent Settlements in the EU	137
3.3	The Decisions from the Commission	140
3.4	Ongoing Investigations	143
4	Conclusion	144
US Materials		144
EU Materials		145
References		146
Co-marketing and Co-promotion Agreements		
<i>Enrico Adriano Raffaelli & Elisa Teti</i>		
1	Introduction	147
2	Co-promotion and Co-marketing Agreements	153

3	Co-promotion and Co-marketing Agreements Examined by Antitrust Authorities	156
4	Co-promotion Agreements Used to Delay Market Entry of Generic Manufacturers: The <i>Johnson & Johnson / Novartis</i> case	161
5	Conclusions	164
The New Unified European Patent Court and a New Patent Law: When a KU is Not a KU		
	<i>Mario Franzosi</i>	167
1	The New UPC: Applicable Rules of Law	167
	1.1 The New UPC	167
	1.2 The Substantive Rules of Law	168
2	The Old Rules of Law	170
	2.1 The Traditional Patent System	170
	2.2 Exclusivity as Specific Object of the Patent Right	171
	2.3 Exclusivity versus License	172
	2.4 Technologies Where Exclusivity Is the Rule (with Exceptions): Pharmaceuticals	174
	2.5 Technologies Where License Is the Rule (with Exceptions): Electronics	176
	2.5.1 Thickets	176
	2.5.2 SEP	177
	2.5.3 NPE	180
3	Conclusion	181
	3.1 The New Rule of Law	181
PART II		
	What Is Going on in National Systems?	183
CHAPTER 3		
	The Perspective from Europe	185
FRANCE		
	Raising Artificial Barriers against Generic Entry: The French Experience	
	<i>Bruno Lasserre</i>	187
1	Introduction	187
2	Background Elements on the Distribution of Generic Medicines in France	188
	2.1 Main Market Entry Requirements	188
	2.2 The Pivotal Role of Pharmacists in the Distribution of Generics	188
3	Identifying Market Distortions Which Impede Generic Entry	191
	3.1 Prices of Generic Medicines and Their Reimbursement	191
	3.2 Repertoire of Generic Drugs: A Limited Listing	192
	3.3 The Denigration of Generics: A French Feature?	193

Table of Contents

4	Barring Market Entry to Generic Medicines: The Case of Denigration	195
4.1	The Plavix Case	195
4.1.1	The Generification of Plavix: A Major Challenge for the Pharmaceutical Sector in France	196
4.1.2	A Strategy of Structured Denigration	196
4.1.3	The Very Atypical Evolution of the Clopidogrel Market	197
4.1.4	Denigration as an Abuse of Dominance	198
4.2	The Subutex Case	199
4.2.1	Proceedings Originated from a Complaint	199
4.2.2	A Comprehensive Plan Conceived to Counter the Arrival of the Subutex Generics	200
4.2.3	The Implementation of the Plan by Schering-Plough	201
4.2.4	A Conduct That Qualifies as an Abuse of Dominance	201
4.2.5	A Fine in Proportion to the Seriousness of the Conduct and Magnitude of the Harm to the Economy	202
4.2.6	A Settlement Accompanied by Commitments	203
5	Conclusions	203
GERMANY		
Patent Settlements and Drug Discount Agreements in Light of European and German Antitrust Law		
<i>Heinz Goddar, Jan Bernd Nordemann & Julian Waiblinger</i>		
1	Introduction	205
2	Patent Settlements in Light of Article 101 (1) TFEU/Section 1 German Act against Restraints of Competition	206
2.1	Settlement Agreements as a Legitimate Means of Resolving Disputes	206
2.2	General Applicability of Antitrust Law to Patent Settlements	207
2.3	Patent Settlements in the Case Law of the German Federal Court of Justice (BGH)	207
2.4	Patent Settlements in the Decision Practice of the European Commission	208
2.4.1	Categories of Patent Settlements	208
2.4.2	Assessment of Individual Clauses in Patent Settlements from an Antitrust Law Perspective	209
2.4.2.1	Agreements Involving Value Transfers to Generic Companies ('Pay-for-Delay'/ 'Reverse Payment' Settlements)	209
2.5	Non-challenge Arrangements in Settlement Agreements	214
3	Antitrust Law Risks of 'Patent Extending' Drug Discount Agreements	215
3.1	Incentive to Conclude Drug Discount Agreements	215
3.2	Violation of National Prohibition of Restrictive Practices (Section 1 German Act against Restraints of Competition)	215

3.3	Abuse of a Dominant or Powerful Market Position (Article 102 TFEU, Section 19, Section 20 German Act against Restraints of Competition)	217
3.4	Conclusion	218
GREECE		
The Status Quo and the Future of the Balance between Patent Law and Competition Law in the Pharmaceutical Sector in Greece		
<i>Ioannis Kokkoris & Alexandra Sidossis</i>		219
1	Introduction	219
2	An Overview of the Greek Legal System	219
3	An Overview of the Greek Patent System	220
4	Seminal Case Law Related to Patents	223
5	An Overview of Greek Competition Laws	224
6	The Generics Market in Greece	231
7	Thoughts on the Status Quo and the Future	235
8	Conclusion	236
Annex: GSK AEVE Case Timeline		237
ITALY		
The Intersection between Competition Law and Intellectual Property Law: The Public Enforcement Approach Followed by the ICA		
<i>Filippo Arena & Roberto Chieppa</i>		239
1	Preliminary Remarks on Public Enforcement: When IP Are Involved	239
2	The Analysis of Effects in Assessing Abusive Practices: The Pfizer Case	242
3	The Analysis By-Object and the Assessment of Effects in Restrictive Horizontal Agreements: The Roche/Novartis Decision	246
ITALY		
Abuse of Patent Rights and Abuse of Dominant Position: The <i>Pfizer</i> Case		
<i>Gustavo Ghidini, Giovanni Cavani & Piera Francesca Piserà</i>		253
1	Introduction	253
2	The Ratiopharm/Pfizer Case	256
3	The Decision of the Italian State Council	257
3.1	Abuse of Right(s)	259
3.2	Abuse of Patent Rights	260
3.2.1	Some Criticisms of the Decision...	262
3.2.2	...And Their Rebuttal	263
4	Beyond Abuse of Dominant Position?	268
Bibliography		269

Table of Contents

ITALY

Antitrust Assessment of Co-marketing Agreements: A Diverging Approach between EU and Italy?

Mario Siragusa & Pietro Merlino 273

1	Introduction	273
2	The Assessment of Co-marketing Agreements under EU Competition Law	275
2.1	Co-marketing Agreements between Non-competitors	275
2.2	Co-marketing Agreements between Actual Competitors	277
2.3	Co-marketing Agreements Entered into with a Potential Competitor	278
2.4	Implications of the Proper Qualification of Typical Co-marketing Agreements (i.e., those between non-competitors) as Vertical Agreements	280
3	Co-marketing Agreements in Italy	284
3.1	The Italian Competition Authority's Approach: The Parties to a Co-marketing Agreement are Invariably Horizontal Competitors	285
3.2	The Far-Reaching Consequences of the ICA's Diverging Approach to Co-marketing: The Italfarmaco Case	288
4	Conclusions	297

NETHERLANDS

Follow the Dutch?

Willem Hoyng & Anne-Claire Hoyng 299

1	Introduction	299
2	The Case Law of the District Court of The Hague	300
3	The ACM	303
4	The Role of the EPO	304
5	Conclusion	305

UNITED KINGDOM

The Pharmaceutical Sector between Patent Law and Competition Law in the UK

Ioannis Kokkoris 307

1	Introduction	307
2	The Legal Framework for IP and Competition in the UK and the EU	311
2.1	Patents and Patent Law	312
2.2	Supplementary Protection Certificates	313
2.3	Other Forms of Regulation and Protection	313
2.4	Infringement Procedures and the Challenge of Patents	314
3	Between Tension, 'Disconnect' and Common Objectives	315
3.1	Common Objectives	315

3.2	‘The Disconnect’	316
3.3	Tensions	317
4	The Theoretical Background of the IP/Competition Tension	319
4.1	The Theoretical Background in the Doctrine	319
4.2	A Theory of Practical Concordance between IP and Competition Law	321
5	The Internalization of Competition Law Considerations into Patent Law and Its Role in Competition Decisions	323
5.1	The Process of Internalizing Competition Considerations into IP Law	323
5.2	The Pro-competitive Doctrines of IP Law	326
5.3	UK Patent Case Law Internalizes Competition Considerations	330
5.4	Conclusion	332
6	The Process of Internalizing Patent Law into Competition Policy	333
6.1	The Competition Cases at the Frontier of IP and Competition in the Pharmaceutical Sector	334
6.2	Reckitt Benckiser and Certain Features of the Introduction of Its Next-Generation Gaviscon Product	334
6.3	GlaxoSmithKline (GSK) and Supply of Paroxetine/Seroxat (‘Pay-for-Delay’)	337
6.4	The Servier Proceedings in the UK	338
6.5	<i>Parallel Import and Chemistree Homeacre Limited v. Abbvie</i>	339
7	Striking the Balance between IP and Competition Law in the Pharmaceutical Sector: Hierarchy or Equal Partners?	339
7.1	The Difficult Task of Striking the Right Balance	340
7.2	IP or Competition: UK’s Approach of Taking into Account the Other Discipline	343
7.3	Conclusion and Outlook	344
UNITED KINGDOM		
IP in the Pharmaceutical Sector in the UK: Some Recent Cases		
<i>Christopher Floyd</i>		
1	Trademarks and Free Movement	345
2	Construction of Second Medical Use Claims	351
UNITED KINGDOM		
Gaviscon: The Diagnosis and Treatment of Abuse of Dominance: Very Recent Changes in the Private Enforcement of Competition Rules in the UK		
<i>Gerald Barling & Renella Reumerman</i>		
1	Introduction	355
2	The OFT’s Gaviscon Decision	356
2.1	Market Definition and Establishing Dominance	360
2.1.1	Abuse	362

Table of Contents

2.2	Some Comments	363
3	Changes to Private Enforcement of Competition Law in the UK	365
CHAPTER 4		
	The International Approach	369
BRAZIL		
	Competition Policy and Life Cycle Management: The Brazilian Experience <i>Ana Paula Martinez</i>	371
1	Overview of Competition Law and Practice in Brazil	371
2	Alleged Anticompetitive Practices in the Pharmaceutical Industry Reviewed by CADE: Drawing the Line for Life Cycle Management Strategies	373
2.1	Boycott against Generic Drugs	374
2.2	Extension of Pipeline Patent Protection	375
2.3	Refusal to Deal	375
2.4	Extension of EMR Due to New Use	376
2.5	Abuse of Data Protection Rights	377
2.6	Ring-Fencing Practices	377
2.7	Launch of Second Generation Drugs	378
3	Expected Future Developments	378
CANADA		
	The Intersection of Canadian Competition and Intellectual Property Law: Developments in the Pharmaceutical Sector <i>Alan Gunderson</i>	381
1	Introduction	381
2	Overview of the Competition Act	382
3	Overview of IPEG	384
4	Overview of Canada's Pharmaceutical Regulatory Regime	385
5	Bureau's Intervention in Apotex/Eli Lilly	386
6	Brand Pharmaceutical Product-Switching Conduct	389
7	Patent Settlements	390
8	Conclusion	393
CHINA		
	The Development of China Antitrust Law and a Review of the Main Decision on the Pharmaceutical Industry <i>Hermes Pazzagliani</i>	395
1	Competition Law in China before the Antimonopoly Law	395
2	Overview of the History of Promulgation of the Antimonopoly Law of the PRC	397

2.1	The Drafting Stage	397
2.2	The State Council Review	398
2.3	The National People's Congress's Approval	398
3	The Antimonopoly Law of the PRC	398
3.1	Contents	398
3.2	Comments on the Antimonopoly Law	402
4	The Enforcement of the Antimonopoly Law in the Pharmaceutical Industry	404
4.1	Roles of Enforcement Agencies	404
4.2	Implementation by the Courts: The <i>Ruibang v. J&J</i> case	405
4.3	Implementation by MOFCOM	407
4.3.1	In General	407
4.3.2	Specific Decisions	408
4.3.2.1	Pfizer Wyeth, Announced with Notice No. 77, (2009)	408
4.3.2.2	Novartis Alcon, Announced with Notice No. 53, (2010)	410
4.4	SAIC	411
4.5	NDRC and the Pharmaceutical Pricing System	411
4.5.1	An Overview of the Pharmaceutical Market in the PRC	412
4.5.2	NDRC: An Overview of the Pharmaceutical Pricing Regulatory System in Force Until 2015	412
4.5.2.1	Notice No. 2142, (2000)	412
4.5.2.2	The Pharma Law	413
4.5.3	NDRC: The 2015 Pharmaceutical Pricing Reform	414
4.5.3.1	The SCNPC Decision	414
4.5.3.2	The NDRC & Others' Notice No. 904, (2015)	414
4.5.3.3	The NDRC Notice No. 918, (2015)	416
4.5.3.4	The NDRC Notice No. 930, (2015)	416
5	Conclusions	417
INDIA		
The Interplay between Competition Law and Intellectual Property in the Indian Pharmaceutical Sector: Deference Is Better than Cure <i>Naval Satarawala Chopra & Yaman Verma</i>		419
1	Introduction	419
2	IP and Competition Law: The Road Thus Far	420
3	Overview of CCI Decisions in the Pharmaceutical Sector in India	422
4	Potential Competition Law Concerns in the Indian Pharmaceutical Sector: Patent Pools	425
5	Competition Law: An Alternative to Compulsory Licensing?	427
6	Conclusion	429

Table of Contents

JAPAN

Japan's Pharmaceutical Industry and the Patent and Non-patent Incentives for Pharmaceutical R&D

Toshiko Takenaka 431

- 1 Introduction 431
- 2 The Pharmaceutical Industry in Japan 433
- 3 Regulatory Approval Process and Data Exclusivity 435
- 4 Patent Protection 438
 - 4.1 Pre-patent Expiration Clinical Trial Safe Harbour 438
 - 4.2 Patent Term Extension 440
- 5 Competition Law: Legality of Reverse Payment Settlement 444
- 6 Conclusion 447

RUSSIA

The Interplay of Patents and Competition Law in the Russian Pharmaceutical Sector: An Everlasting State of Transition

Alexey Ivanov 449

- 1 Relevance of the Russian Experience 449
- 2 The Russian Pharmaceutical Market and Regulatory Regime 452
- 3 Conclusion 456

SOUTH AFRICA

The Intersection between Patent Law and Competition Law as It Relates to the Pharmaceutical Sector in South Africa

Daryl Dingley 459

- 1 Introduction 459
- 2 Competition Law Exemptions for the Exercise of Patent Rights 461
- 3 Competition Challenges and Remedies in Relation to the Exercise of Pharmaceutical Patent Rights 463
- 4 Compulsory Licensing of Pharmaceutical Patents in South Africa for Abusing a Patent Right 469
- 5 Competition Issues Arising from the South African Patent System 472
- 6 Conclusion 475

UNITED STATES

Pharmaceutical Antitrust Law in the United States

Michael A. Carrier 477

- 1 Markets 477
- 2 Regulatory Regime 478
- 3 Generic Entry 479
- 4 Product Hopping: General 479
- 5 Product Hopping: Case Law 480

Table of Contents

6	Settlements	483
6.1	Settlements and Product Hopping	485
6.2	Authorized Generics	485
7	Conclusion	487
	Index	489

The Dangers of Settling Patent Litigation

Ian S. Forrester*

1 INTRODUCTION

The intrinsic tension between competition law and IP law has nourished many academic dissertations and has been at the core of several celebrated competition cases. I have written about this tension in such articles as *Magill Revisited*¹ and *Compulsory Licensing in European Competition Law: The Power of the Adjective*.² These cases often involve a conflict between ‘free competition’ on the one hand and on the other hand the classical exercise of an IP (closing down a copyright infringer, refusing to grant a licence). Sometimes, however, they involve an exercise of the right which is disputed as a matter of IP law (like invoking a trademark against the sale of non-spurious goods imported via parallel trade or tying to the licensing of a right acceptance of an obligation not conferred by that right). In the early cases, which came to the ECJ under the Treaty’s provisions on free movement, the reason for condemning the invocation of the IP right was often conflict with the policy of market integration, as in the many *Centrafarm* cases from the 1970s:³ there the holder of parallel patent or trademark rights in several Member States tried to block the sale of genuine goods to prevent parallel traders profiting from the differences in price in adjoining Member

* The opinions expressed are wholly personal. The law is stated as of December 2014, and may well evolve during the next five years.

1. See I. GOVAERE, R. QUICK, M. BRONCKERS, *Trade and Competition Law in the EU and Beyond*, Festschrift for Jacques Bourgeois (Elgar Publishing, 2011).
2. See I. FORRESTER, K. CZAPRACKA, *Compulsory Licensing in European Competition Law: The Power of the Adjective*, in S. ANDERMAN, A. EZRACHI (eds) *Intellectual Property and Competition Law: New Frontiers* (Oxford University Press, 2011).
3. See Case 15/74, *Centrafarm, BV v. Sterling Drug, Inc.*, 1974 E.C.R. 1147, [1974] 2 C.M.L.R. 480 (1974); Case 16/74, *Centrafarm, BV v. Winthrop, BV*, 1974 E.C.R. 1183, [1974] 2 C.M.L.R. 480 (1974); Case 107/76 *Hoffmann-La Roche AG v. Centrafarm Vertriebsgesellschaft Pharmazeutischer Erzeugnisse mbH*, [1977] ECR 957; Case C-102/77, *Hoffmann-La Roche & Co. v. Centrafarm Vertriebsgesellschaft Pharmazeutischer Erzeugnisse, GmbH*, 1978 E.C.R. 1139, [1978] 3 C.M.L.R. 217 (1978).

States. In the early cases, the European Court drew a distinction between core rights and ancillary rights (these are my glosses as existence and exercise were the words used), to justify a conclusion that the Treaty of Rome permitted the intervention of European law principles against obstacles to cross border trade. Those judicial theories were subsequently invoked in competition cases to argue that competition law could not constrain the assertion of a core or essential IP right, an assumption which subsequent cases such as *Magill*⁴ and *Microsoft*⁵ have shown to be ill-founded.

The topic described in this chapter is much more innovative, going to the core of the privileges conferred by IP law: it is a new kind of controversy, relating to the settlement of patent disputes. The topic originally became hot in the United States over the past ten years due to the quirks of US legislation about the status of generic competitors: they were encouraged by statute to enter the market, towards the end of the life of the patent, on favourable terms. As a result, litigation in the US offered a regulatory prize, and settling litigation became correspondingly more significant.

Officials have pursued the idea that there might be a comparable public interest in the EU, despite the different regulatory regime, in attacking agreements which settle litigation over whether a patent is valid or is infringed. How should competition law regard the settlement of a dispute over whether a patent on a pharmaceutical invention was validly granted and is infringed by a generic version of the original product? Is the settlement to be welcomed as a desirable resolution of an expensive and uncertain dispute, or should it be regarded as a scheme to perpetuate the existence of a patent of dubious validity, with the consequence that generic entry is postponed, to the detriment of tax payers in the sense that public health budgets have to purchase patented medicines during a longer period? Is there a competition law duty to prefer a judicial determination of a controversy over a contractual resolution of the controversy in which contract each side gets an outcome which is better than it feared but worse than it hoped?

2 SOME ECONOMIC AND REGULATORY CONTEXT

It may be helpful to begin by recording some of the context which may reveal a rationale for the recently adopted policy. Pharmaceutical medicines in European countries are sold in pharmacies to patients who have received prescriptions from doctors. In most EU Member States, the state pays a portion, sometimes a large portion, of the price paid by the patient, and also the state usually prescribes the price. The more novel the medicine, the more elevated the price: governments set the price they are willing to pay in function of the therapeutic value of the medicine, and the price of other medicines in the same category. The price of patented medicines is usually higher than medicines no longer covered by patents (so-called generics). The shorter the period of patent protection, the sooner the price will fall; thus in Europe it can be

4. C-241/91 P and C-242/91P Judgment of the Court of 6 Apr. 1995, *Radio Telefís Éireann (RTE) and Independent Television Publications Ltd (ITP) v. Commission*, ECLI:EU:C:1994:210.

5. T-201/04 Judgment of the Court of First Instance (Grand Chamber) of 17 Sep. 2007, *Microsoft Corp. v. Commission*, ECLI:EU:T:2007:289.

argued that the challenging of the patent by a generic competitor is a merit, a public advantage, which may lead (if the court were to find that the patented invention had not been infringed or the patent itself had been wrongly granted) to a reduction of the country's health budget. Of course, it can also be noted that pharma companies make intense research to develop tomorrow's drugs using the revenues earned by selling patented medicines today. So if the patent is upheld the extra expense is not 'lost' to the public interest in that a percentage of the revenues thus earned will be spent on research by the patentee.

There is a related policy concern which has been articulated during the sector enquiry into the pharmaceutical industry, launched by Commissioner Kroes on 16 January 2008: that pharmaceutical inventors, instead of being content with the well-established years of patent protection deservedly accorded to the basic molecule, may additionally seek to get patent protection for complex steps in the production process which makes that molecule efficiently on an industrial scale. Thus a generic competitor would have to develop its own solutions to avoid the techniques covered by the process patents. As generics like quick low-price industrial operations, they prefer to make a product which is easy to copy or replicate. There may be a suspicion that these process patents are less worthy of respect than the original patents on the molecule itself. This policy approach (assuming it exists) confronts the problem that all patents are granted after extensive research by skilled patent examiners who have access to millions of publications about the prior art. They do not grant patents lightly. It is not easy to say that the European Patent Office (EPO) is systematically wrong, and it would be astonishing to argue that the competition law is a good remedy for any supposed over-generosity of the patent examiners at the EPO.

However, there is unquestionably suspicion about any agreement which appears to insulate a pharma patent from future challenge, and a readiness to assume that the agreement implementing a settlement of the dispute can be assessed by focusing on its prohibition of future challenges rather than by the saving of expense and effort which a settlement delivers.

One way of regarding a settlement is as a device to bring an end to an expensive and uncertain dispute. Another way of regarding a settlement is as a device to share a market between two natural competitors. The new, currently fashionable, theory is that while settlements are in theory desirable, their terms are to be reviewed so sceptically that genuine settlements of genuine disputes risk condemnation on the theory that they contain contractual restrictions typical of a settlement involving mutual concessions, by which each side binds itself to accept less than it might have hoped for at the moment the litigation was initiated. The settlement will exclude further litigious challenges.

As often happens when a major competition case is unfolding, the opposing theories are sharply opposed. The defending pharma companies say that a settlement makes commercial sense for both sides; every litigation presents a risk, the Courts are incapable of deciding all initiated litigations, and ending a dispute must be a public good. The competition enforcer says that of course settlements are to be welcomed, but

that there can be no immunity for anti-competitive agreements by labelling them settlements. Thus, when the settlement does no more than agree that a patent litigation has ended, it is acceptable. However, say the prosecutors, bad settlements which involve additional unacceptable features are to be condemned.

3 VALUE TRANSFERS

A 'value transfer' is the term attributed to a commercial advantage delivered by the inventor/patentee to the generic alleged infringer: this may be a new business opportunity or a payment or some other concession which is granted in order to make a conclusion of the litigation acceptable. Surely, says the critic, if the wrongdoer really was the wrongdoer and really was infringing the patent, the patentee would relish the chance of a crushing victory in court? Why should the confident patentee give a piece of business or a lump of money to the dishonourable generic who is violating a vital patent? Therefore, on this theory, any restrictive terms in the settlement agreement, even if they are typical of a settlement agreement, are manifestations of anti-competitive intent. Thus acknowledging that the patent is valid and promising not to infringe it are restrictions on the generic's freedom of action. This is true even if the generic had lost at first instance (since it could have appealed). This is true even if the generic had chosen to abandon the litigation, because it had no product to launch if the patent were annulled (since it might have been able to solve the biochemical purity problems which had thus far denied it a license to sell its products). This is true even if the generic producer would stand to lose millions if it lost the appeal or if it would have needed two years to develop a non-infringing technique to avoid the patent. Each of these commercial or regulatory difficulties might have been solved so the generic remained a potential competitor. And, last but not least, it is true even if the patentee settles a few parallel litigations and pursues the others to the bitter end. Generic litigants A through E fight; generic litigants F and G settle. The judicial examination is not thereby avoided. Yet, there is a gross infringement.

These elements, which do indeed seem surprising, confirm the extremely severe view taken of settlements as soon as they involve the conferring of anything that looks like a benefit to the generic company.

4 ANTI-COMPETITIVE SETTLEMENTS

Can there be settlements which are truly anti-competitive? Yes, assuredly. Where the 'settlement' is not a settlement of a genuine dispute about validity or infringement but in truth involves nothing more than a bribe to induce one party to stop competing, or where the 'settlement' imposes restrictions going beyond the scope of the patent (the patent covers the production of green tooth brushes and the 'settlement' covers the marketing of all hygienic products), or if the original patent was obtained by fraud (the laboratory reports were faked), the public prejudice and anti-competitive effect is

evident. The *Süßhofer*⁶ case reminds us that there is no immunity for the terms of settlement agreements just because they are settlements. But that case does not create a duty to litigate!

Litigators are professional combatants. They gather the facts, they test the witnesses, they master the key three or four points on which victory or defeat will hinge, and they anticipate the weaknesses of the opposition and of the client. In a vigorously contested case, only a fool would promise victory. Any prudent lawyer would say something like ‘good chances’, ‘65/35’, or ‘It all depends on Professor Smith’. Any prudent lawyer will initiate with his client discussion of a possible settlement, and in most cases settlement talks will be broached. And it is in the cases where the outcome is most unsure that the pursuit of a settlement makes most sense. It seems troubling to imagine that Commission policy favours litigation to the bitter end, even after defeat at first instance. The policy seems not to distinguish between the situations that are very different. One situation is where for example four weeks before the trial of a litigation which will be vital to the commercial future of the key product of the patentee the trial lawyers feel unsure about the outcome because for example the witnesses are less convincing than when they first gave their story to the lawyers, or the expert has published an article which seems to contradict his technical report. As a result of these fresh uncertainties there is a genuine doubt about the wisdom of going on with litigating an expensive and important case. The second situation is where the patent has been obtained by fraud and the company is keen to avoid scrutiny, and is willing to pay a lot to be left in peace to exploit it. Yet those situations are hugely different and a policy that treats them as equally objectionable seems puzzling indeed.

5 PRE-TRIAL NERVOUSNESS AND UNCERTAINTY

Any practitioner who has conducted litigation will know that the possibility of a settlement is almost always discussed, and often several times, as the case moves forward. It is in finely balanced litigation where the outcome is the most uncertain and where the result may mean life or death for one side or the other that it makes sense to consider the risks and to consider mutual concessions. Roman law⁷ and the Bible⁸ each favour settlements. In some countries, such as England, an attempt to settle is a legal requirement for initiating litigation. Judges will often agree to delay a hearing to permit the parties to reach a deal. But, if a settlement is reached, it must contractually eliminate the possibility of future disputes on the same topic. All the terms must be borne in mind, not only the ones which prevent a rerun of the dispute.

It is easy to grant competition law blessing where one side is in an overwhelmingly strong position to reach a deal whereby one side wins and the other surrenders,

6. C-65/86 Judgment of the Court of 27 Sep. 1988, *Bayer v. Süßhofer*, ECLI:EU:C:1988:448, para. 121.

7. *Interest rei publicae ut sit finis litis*.

8. ‘As you are going with your adversary to the magistrate, try hard to be reconciled on the way, (or your adversary may drag you off to the judge, and the judge turn you over to the officer, and the officer throw you into prison).’ Gospel of St Luke, Ch. 12, v. 58, NIV.

with perhaps some concessions about legal fees. But it is difficult where, for example, the expert who will testify is at risk of not being understood, and the laboratory reports are equivocal, or where there are several cases running in different courts, so that possible victory in France may be too late to prevent generic entry and exports from France to other countries are likely. Yet these are the very situations where concessions are necessary to make the gap bridgeable.

6 THE PUBLIC INTEREST?

There is a potential public interest in the outcome of many disputes – patents over non-pharmaceutical matters, professional negligence, discrimination or harassment in employment, to name but a few. There is equally a strong interest for the parties (either side or both sides) in avoiding public disclosure of their dispute. An arbitration about whether unlawful state aid was granted, or a dispute about the pay of one part-time worker may have huge implications for one of the parties, much wider than the single dispute. So it is not the case that disputes about pharma patents are uniquely unfitted to resolution by settlements.

If there is a public interest in seeing litigation about pharmaceutical patents carried forward to a judicial conclusion, why not apply the same rule to engineering or electronic patents? Indeed by the same logic, there is a public interest in seeing a judicial determination of controversies about harassment in the workplace, dangerous food additives, unhealthy or unsafe premises or negligent lawyers or doctors. It would be surprising to imagine that a settlement of a litigation about any such matter would be anti-competitive if it involved mutual concessions, whereby each party got some advantage.

I suggest that there is a manifest difference between the settlement of a litigation on the one hand, and an agreement to remove a competitor from the market on the other. The first has overwhelming social, legal and economic benefits, at the price of compelling the parties to eschew future combat on the same topic. The second has pro-competitively nothing to commend it. Millions of Euros a year is a lot of money, yet such is the price of a hotly contested patent litigation which is fought out in several countries since patents are enforced nationally in the courts of twenty-eight Member States and imposes ancillary restrictions. We ought not to assume that a deal which ends expensive litigation is no more than a market sharing plot.

7 THE OVERUSE OF THE NOTION OF RESTRICTION ‘BY OBJECT’

It is perplexing to see that current policy is moving towards condemning settlements which involve mutual concessions or ‘value transfers’, without proper enquiry into whether on balance the deal was desirable in competitive terms. Did the litigation about validity continue as between the patentee and other generics, despite the settlement with one generic? Had the generic company valid reason to wish to stop the fight, either because victory would bring it little benefit or would cost too much? Do the risks at stake make any difference? Suppose that the generic did not hope to make

a lot of money even if it won the patent case: Does that excuse its trying to bluff and do an advantageous settlement? Was the threat to the prosperity of the patentee huge, so that it had a high incentive to explore a settlement involving significant concessions? Is the asymmetry of risk (it means a lot to the patentee who hopes to enjoy a full patent term of twenty years in seventeen Member States and fifty in the wider world, but not much to the generic, who will make little or no money unless it can launch its new product legally and quickly) relevant?

I suggest that it ought to be relevant that the parties were confronting genuine business problems that complicated the analysis of whether to continue litigating since there was a fair chance that judicial victory would not confer commercial advantage. Yet it seems the duty to litigate overrides such common sense considerations.

I regret the recently fashionable practice of describing complex contractual relationships as restrictions ‘by object’. Such textual condemnations cannot be used casually as a supplementary ground of objection to a controversial practice. I suggest that it is wise to limit the use of the term ‘by object’ to easy cases where the harm to competition *fait crever les yeux*. Where the merits and demerits of the contract are finely balanced, where it conferred advantages and burdens on each side, where chemical, medical or economic opinion is divided, then slogans are not helpful to the analysis. It is by looking calmly at the effects that one can reach a reliable conclusion. The term ‘by object’ should not be used as an excuse to avoid precise analysis of what harms and benefits the agreement may confer.

8 WHERE ARE THE LIMITING PRINCIPLES?

It is routine in competition cases about the use and abuse of IP rights for the issue to be presented as a clash between absolutes. The right holder says that it has ‘merely’ invoked a privilege granted by statute and that to deny it this right takes away the essence of the property right. The complainant points to wholesome competition, the end of abuses, freedom of choice, lower prices and all sorts of other benefits. These slogans are easy to utter. It is indispensable to have clear limiting principles. The seminal cases of *Volvo/Veng*⁹ and *Magill*¹⁰ provided such clarifications. But it is quite unclear in the area we are discussing what are the crucial elements whose presence or absence will reveal that the settlement is anti-competitive or not.

‘Uncertainty about the outcome’ of the litigation is deemed important, but that is a meaningless test since uncertainty is universal on the eve of trial. It is equally risky to settle by mutual concession with a ‘value transfer’ where the patent is crucial to the company’s business even where multiple litigations involving other parties about the same patent continue. The current approach seems to make no distinction between how confident the patentee feels of victory or how objectively strong the patent is thought to be. Of course it is not the job of the competition authority to decide whether

9. C-238/87 Judgment of the Court of 5 Oct. 1988, *AB Volvo v. Erik Veng (UK) Ltd.*, ECLI:EU:C:1988:477.

10. See *supra* n. 4, *Radio Telefis Eireann (RTE) and Independent Television Publications Ltd (ITP) v. Commission*.

a patent is ‘weak’ or ‘strong’, but it is strange that the words of the settlement are more important than the reasons to settle. Putting it differently, the merits of the underlying patent dispute seem to make no difference to the analysis of the legality of the terms of the settlement. The fact that it made commercial sense to settle seems likewise irrelevant. Settling after a defeat in court seems no better, since a settlement promises there will be no appeal.

Until clarification has been obtained, it seems to be risky to conclude patent litigation as to pharmaceuticals other than by a total victory or total defeat before a judge.

9 WHAT PRECISELY IS THE ILLEGAL CONDUCT?

If we are going to review the context let us consider all pertinent issues. Does the policy affect litigation only as to pharmaceutical patents, on the rationale that governments pay for drugs? If so, what about patents relevant to the road-building industry or military equipment which would affect the state’s budget? If not, is the pharma industry morally inferior or more prone to abuses than other industries? Does the campaign threaten other settlements of other cases where there is a public interest in the clarification of the legal issue in dispute? If the pharmaceutical industry is uniquely in need of the policy, let this be stated and explained.

A related manifestation of the current muddle is prolixity. The decisions in which the European Commission implements its policy are far too wordy. It is impossible to know at the end of 500 pages exactly what conduct was deemed reprehensible. The file may well contain inflammatory emails with military metaphors (‘crush them’, ‘nuke them’, ‘no mercy’, or the like), but they do not define what is unlawful. Email communications which threaten destruction to the competitive enemy may be fun to quote from and colourful to invoke as showing hardness of heart and a harsh approach to competitors. But it is not unlawful to voice competitively hostile thoughts. What is needed is not chapters of ‘context’ but two pages of carefully articulated explanation of what the offence against competition law consists of, placed fairly alongside all relevant considerations.

If the supposed breach of the law is so clear that it deserves to be damned as a ‘by object’ infringement, so plain that there is no need to enquire into its effects, then the legal community, the technology community and the world’s patentees are entitled to demand intelligible and rational articulation of the core of illegality. Yet the decisions which have so far appeared are hundreds and hundreds of pages too long. This wordiness sows confusion and uncertainty and makes daunting the tasks of judicial review. The *Volvo/Veng* judgment set forth the key findings in two celebrated paragraphs, and the *Magill* decision from the Commission was only nine pages long.

10 A PATENT JUDGE COMMENTS

One of the other contributors to this volume is a distinguished and experienced patent judge, Sir Robin Jacob. I recollect that he was invited to address a large gathering to

mark the Commission's pursuit of its vast enquiry into the pharmaceutical industry. He astonished the listeners by excoriating the assumptions, techniques and conclusions of the sector enquiry. He said it was 'a disgraceful use of the Commission's powers', and of a key theory 'that was entirely nonsense'. Sir Robin said that the preliminary report was 'appalling'.¹¹ It revealed 'a vast ignorance on the Commission's part as to how the patent system actually works'. He noted that since there is a lot of money involved, generic companies naturally challenge big pharma patents if there is a realistic possibility of winning. And patentees invoke their patents if there is a realistic possibility that they may be held valid. Indeed, I would suggest that there is a structural need for litigation: it is the mechanism whereby the validity of a valuable grant is tested. But there is no merit in compelling those who start a litigation to carry it forward to the bitter end. Sir Robin noted that 'The normal case is where there is a real uncertainty about validity. Neither sides know who would win. The prospective legal battle, if it takes place, will be expensive and time consuming.' However, at the time of the agreement, no one knows whether it is valid or not. That could only be determined by the end of the final appeals in the very battle the agreement is designed to avoid. If these agreements are treated *ipso facto* as anti-competitive, there is only one alternative: litigation to the death. I presume that the Commission would deny any such bleak intention, but it is striking that a very experienced national patent judge asks such basic questions years after the new policy has been adopted, which brings me to a conclusion.

11 CONCLUSION

When I was a young lawyer in Brussels last century, the competition law world was dominated by the parsing of the implications of Article 85 (1) of the EEC Treaty. As then interpreted by the European Commission, its reach was very broad. It caught not just agreements which were intrinsically bad (like a market sharing agreement) but those which had some pro-competitive and some anti-competitive features. This reflected the Commission's understandable nervousness about trusting business people, officials and even judges to apply sound doctrine when applying the unfamiliar concepts of Article 85. The official line was clear: if in doubt, come to the public authority, notify the agreement and request administrative blessing. In reality, the system functioned very differently as practitioners tried to game the system to win procedural advantage, while the Commission found restrictions of competition in almost anything while being reluctant to grant individual exemptions. The system was a procedural curiosity perhaps appropriate to an infant system. Its intellectual flaw was looking at words on a page rather than reality and effects.

I suggest that an excessive reliance on the 'by object' damnation echoes the error of the 1970s and 1980s. Competition takes many forms. It is the consequence of many actions and many phenomena. The reality of how the competitive process works is not

11. R. JACOB, *Competition Authorities Support Grasshoppers: Competition Law as a Treat to Innovation*, available at <http://fordhamipconference.com/wp-content/uploads/2014/10/6A-2-Jacob-Robin-paper.pdf>.

easy to grasp or to measure. Many actions and many agreements have positive and negative effects. I sell my business and promise not to enter the same line of commerce for five years: that stops my competing with the buyer, earns me a higher price and reassures the buyer that he will be able to approach my customers confident that I have withdrawn. Is that a bad clause or a good clause? It likely has both features: maybe five years is too long, but maybe it is acceptable. A bald promise not to compete for five years is a clear infringement, but such promise as part of a pro-competitive acquisition of my business may be acceptable.

We ought not to revert to the easy days of condemning by reference to words and little else. There can be settlements of sham litigation which are clearly infringements. Those should be challenged robustly. But it is deeply unconvincing to approach the carefully negotiated conclusion of a bitter, costly and uncertain litigation as being inexcusably bad because it involves a 'value transfer' and ended a litigation as to the outcome of which there was 'doubt'. The topic requires much more careful analysis and better examination of all relevant factors. Discouraging the settlement of true disputes by prohibiting the parties from bridging the gap between them is bad policy and ought I suggest not to be good law.